Overview
Bicycle Therapeutics plc, headquartered in Cambridge, UK, operates primarily in the biotechnology industry and focuses on developing transformative medicines through its proprietary bicyclic peptide (Bicycle®) technology. This innovative technology platform enables the creation of new classes of therapeutics which possess the affinity and specificity typical of antibodies, coupled with the tissue penetration ability of small molecules, aimed at treating cancer and other debilitating diseases. Key projects include their lead candidates BT1718, a novel Bicycle Toxin Conjugate targeted at tumors expressing Membrane Type 1 Matrix Metalloproteinase, and BT5528, a second-generation Bicycle Toxin Conjugate aimed at the EphA2 receptor, a target associated with poor prognosis cancers. Their approach to drug development pioneers avenues in oncology, specifically using a tumor-targeted immune cell agonists strategy to activate immune responses against cancers.
Basic Stats
The share price of Bicycle Therapeutics plc - Depositary Receipt (Common Stock) as of September 5, 2025 is $7.14 / share. This is a decrease of -3.25% from the prior week. The market cap (or net worth) of Bicycle Therapeutics plc - Depositary Receipt (Common Stock) as of September 5, 2025 is $494.47 MM.
The Factor Analysis chart (below right) shows a view of Bicycle Therapeutics plc - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 494.47 MM |
| EV | -226.98 MM |
| Shares Out. | 69.25 MM |
| Earnings Date | |
| EPS (TTM) | -3.50 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.30 |
| Short Shares Avail. | 0.65 MM |
| Short Interest | 1.65 MM |
| Short Float | |
| Days to Cover | 9.34 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -65.05 % |
| Volatility (1 yr) | 0.72 |
| Beta | 1.17 |
| Sharpe Ratio (1 yr) | -0.97 |
| Sortino Ratio (1 yr) | -1.52 |
| PE Ratio | -2.04 |
| Price/Book | 0.74 |
| Price/TBV | 0.74 |
| Book/Market | 1.35 |
| EBIT/EV | 1.09 |
| EBIT(3yr avg)/EV | 0.81 |
| ROA | -0.23 |
| ROE | -0.28 |
| ROIC | -0.36 |
| CROIC | -0.35 |
| OCROIC | -0.31 |
| Implied Volatility | 193.12 % |
| Put/Call OI Ratio | 0.63 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Bicycle Therapeutics plc - Depositary Receipt (Common Stock) is $24.91. The forecasts range from a low of $10.10 to a high of $46.20. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Bicycle Therapeutics plc - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-05 | EF Hutton | Buy | Initiate | |
| 2022-11-09 | JMP Securities | Market Outperform | Maintains | |
| 2022-09-12 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-08-31 | Cowen & Co. | Outperform | Initiate | |
| 2022-08-22 | SVB Leerink | Outperform | Maintains | |
| 2022-08-05 | SVB Leerink | Outperform | Maintains | |
| 2022-08-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-07-28 | Barclays | Overweight | Initiate | |
| 2022-05-23 | Piper Sandler | Overweight | Maintains | |
| 2022-05-06 | SVB Leerink | Outperform | Maintains | |
| 2022-04-13 | B. Riley Securities | Buy | Neutral | Downgrade |
| 2022-04-12 | Needham | Buy | Maintains | |
| 2022-03-03 | JMP Securities | Market Outperform | Maintains | |
| 2022-02-14 | Morgan Stanley | Equal-Weight | Initiate | |
| 2021-12-17 | SVB Leerink | Outperform | Initiate | |
| 2021-12-09 | Needham | Buy | Initiate | |
| 2021-10-14 | JMP Securities | Market Outperform | Maintains | |
| 2021-10-08 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-09-30 | B. Riley Securities | Buy | Initiate | |
| 2021-07-15 | Canaccord Genuity | Buy | Maintains | |
| 2021-07-13 | Canaccord Genuity | Buy | Maintains | |
| 2021-05-07 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-04-20 | JMP Securities | Market Outperform | Initiate | |
| 2021-01-15 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-10-12 | Cantor Fitzgerald | Overweight | Initiate | |
| 2020-09-10 | Canaccord Genuity | Buy | Maintains | |
| 2020-06-12 | Oppenheimer | Outperform | Initiate | |
| 2019-11-14 | Roth Capital | Buy | Initiate | |
| 2019-09-11 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2019-06-17 | Piper Jaffray | Overweight | Initiate | |
| 2019-06-17 | Jefferies | Buy | Initiate | |
| 2019-06-17 | Goldman Sachs | Neutral | Initiate | |
| 2019-06-17 | Canaccord Genuity | Buy | Initiate | |
| 2023-02-15 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-15 | EF Hutton | Buy | Reiterate | |
| 2023-02-15 | Needham | Buy | Reiterate | |
| 2023-03-01 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-03-01 | Needham | Buy | Maintains | |
| 2023-02-28 | EF Hutton | Buy | Reiterate | |
| 2023-02-27 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-04-18 | JMP Securities | Market Outperform | Reiterate | |
| 2023-04-19 | EF Hutton | Buy | Reiterate | |
| 2023-05-11 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-05-08 | Oppenheimer | Outperform | Reiterate | |
| 2023-05-05 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-05-05 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-05 | Needham | Buy | Maintains | |
| 2023-09-12 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-09-12 | Needham | Buy | Buy | Reiterate |
| 2023-09-11 | B. Riley Securities | Neutral | Buy | Upgrade |
| 2023-12-20 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-08-04 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2023-08-04 | JMP Securities | Outperform | Outperform | Maintains |
| 2023-08-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-04 | Needham | Buy | Buy | Maintains |
| 2023-09-12 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-09-12 | B. Riley Securities | Neutral | Buy | Upgrade |
| 2023-12-15 | Needham | Buy | Buy | Maintains |
| 2023-09-07 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-03 | EF Hutton | Buy | Reiterate | |
| 2023-11-08 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-04-10 | Needham | Buy | Buy | Reiterate |
| 2024-05-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-21 | Canaccord Genuity | Buy | Buy | Reiterate |
| 2024-02-21 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-02-21 | Needham | Buy | Buy | Reiterate |
| 2024-11-08 | Stephens & Co. | Equal-Weight | Initiate | |
| 2024-11-01 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-11-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-31 | Needham | Buy | Buy | Reiterate |
| 2024-12-18 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-09-16 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-09-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-16 | Needham | Buy | Buy | Reiterate |
| 2024-12-13 | B. Riley Securities | Neutral | Neutral | Maintains |
| 2024-08-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-07 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-08-07 | Needham | Buy | Buy | Reiterate |
| 2024-08-07 | B. Riley Securities | Buy | Neutral | Downgrade |
| 2025-03-11 | Needham | Buy | Buy | Reiterate |
| 2024-10-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-24 | Needham | Buy | Buy | Reiterate |
| 2024-09-06 | RBC Capital | Outperform | Initiate | |
| 2025-02-26 | Needham | Buy | Buy | Reiterate |
| 2024-09-09 | Needham | Buy | Buy | Reiterate |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2025-01-22 | Stephens & Co. | Equal-Weight | Equal-Weight | Reiterate |
| 2024-12-16 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-01-13 | Needham | Buy | Buy | Reiterate |
| 2025-01-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-26 | Citizens Capital Markets | Market Outperform | Market Outperform | Reiterate |
| 2025-02-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-01 | Barclays | Overweight | Overweight | Maintains |
| 2025-04-09 | Needham | Buy | Buy | Reiterate |
| 2025-07-17 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-08-12 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-08-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-02 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-05-02 | Needham | Buy | Buy | Reiterate |
| 2025-05-02 | B. Riley Securities | Neutral | Neutral | Maintains |
| 2025-05-02 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-05-06 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-08-11 | Oppenheimer | Outperform | Outperform | Maintains |
